Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

308.17USD
26 Aug 2016
Change (% chg)

$1.32 (+0.43%)
Prev Close
$306.85
Open
$307.21
Day's High
$310.74
Day's Low
$304.56
Volume
1,124,177
Avg. Vol
1,916,312
52-wk High
$333.65
52-wk Low
$223.02

BIIB.O

Chart for BIIB.O

About

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA,... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $67,526.45
Shares Outstanding(Mil.): 219.12
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 17.99 36.93 36.63
EPS (TTM): 17.13 -- --
ROI: 23.33 14.69 14.12
ROE: 31.85 15.48 15.04

BRIEF-Biogen announces Bioverativ as name of new hemophilia-focused company

* Biogen announces Bioverativ as name of new hemophilia-focused company

Aug 09 2016

Biogen not pursuing a sale: source

U.S. biotechnology company Biogen Inc has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers, according to a person familiar with the matter. | Video

Aug 04 2016

Biogen not pursuing a sale - source

Aug 3 U.S. biotechnology company Biogen Inc has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers, according to a person familiar with the matter.

Aug 03 2016

BRIEF-Allergan has no interest in a Biogen deal - CNBC, citing sources

* Allergan has no interest in a Biogen deal - CNBC, citing sources

Aug 03 2016

BRIEF-Amyris enters partnership with Biogen

* Collaboration will explore use of Amyris's microbe engineering technology

Aug 03 2016

Biogen draws takeover interest from Merck, Allergan: WSJ

Biotechnology company Biogen Inc  has drawn takeover interest from drug companies including Merck & Co Inc and Allergan Plc , The Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Aug 02 2016

UPDATE 4-Biogen draws takeover interest from Merck, Allergan-WSJ

Aug 2 Biotechnology company Biogen Inc has drawn takeover interest from drug companies including Merck & Co Inc and Allergan Plc, The Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Aug 02 2016

BRIEF-Allergan unlikely to pursue Biogen deal- CNBC,citing source

* Allergan unlikely to pursue Biogen deal- CNBC,citing source (Bengaluru Newsroom: +1-646-223-8780)

Aug 02 2016

UPDATE 3-Biogen draws takeover interest from Merck, Allergan -WSJ

Aug 2 Biotechnology company Biogen Inc has drawn takeover interest from drug companies including Merck & Co Inc and Allergan Plc, The Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Aug 02 2016

Wall St. falls as weak auto sales spur growth jitters

NEW YORK Wall Street stocks fell on Tuesday, with each of the major indexes notching their worst day in about a month as economic data and weaker-than-expected auto sales spurred concerns about growth.

Aug 02 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $119.04 +0.47
Pfizer Inc. (PFE.N) $34.82 +0.05
Novartis AG (NOVN.S) CHF77.40 --
Merck & Co., Inc. (MRK.N) $62.85 +0.53
Roche Holding Ltd. (ROG.S) CHF240.90 --
Roche Holding Ltd. (RO.S) CHF242.00 --
Bayer AG (BAYGn.DE) €97.00 --
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €69.35 --
GlaxoSmithKline plc (GSK.L) 1,649.50p -3.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$25.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.